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SUMMARY – Creutzfeldt-Jakob disease (CJD) is a rare, fatal neurodegenerative disease caused 
by an infectious protein called prion and is characterized by spongiform changes, neuronal loss, re-
active astrocytic proliferation and accumulation of pathologic cellular protein, occurring in 3 general 
forms: sporadic or spontaneous, genetic or familial, and acquired form including a variant form of 
CJD. Clinical presentation of CJD is characterized by progressive dementia, neurologic symptoms 
and visual impairment, development of akinetic mutism, and eventually death, usually from respi-
ratory infection. Th e diagnosis is based on clinical presentation, electroencephalogram, and typical 
cerebrospinal fl uid and magnetic resonance imaging fi ndings. A case is presented of a 56-year-old 
woman with progressive dementia, typical neurologic symptoms, positive cerebrospinal fl uid and 
typical magnetic resonance imaging fi ndings. Th e clinical, pathologic and imaging fi ndings of this 
rare condition are also discussed.
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Introduction
Transmissible spongiform encephalopathies or 
prion diseases are rare, fatal disorders caused by in-
fectious protein called prion, and characterized by 
myriads of vacuoles in the brain giving it a ‘spongy’ 
appearance under the microscope. Th ey aff ect animals 
and humans: the most common forms of prion disease 
in animals are scrapie in sheep and bovine spongiform 
encephalopathy (BSE) in cattle. For the fi rst time in 
history, scrapie was recorded in the 18th century, while 
the BSE or mad cow disease epidemic fi rst became 
evident in 1985 in the United Kingdom (UK): cattle 
were infected by consumption of meat and bone meal 
nutritional supplements contaminated with scrapie-
infected sheep carcasses1. 
Human spongiform encephalopathy was fi rst de-
scribed in 1920 by two German neurologists, Hans 
Gerhard Creutzfeldt and Alfons Maria Jakob, thus 
called Creutzfeldt-Jakob disease (CJD). Th e world-
wide prevalence of CJD is one person per 1 million, 
while the annual incidence is one person per 2 mil-
lion, showing a slight female predominance2. CJD 
is characterized by progressive dementia, neurologic 
symptoms and impaired vision, and eventually death 
in terminal stage. Clinical presentation, positive CJD 
biomarkers in cerebrospinal fl uid (CSF), electroen-
cephalogram (EEG) and typical magnetic resonance 
imaging (MRI) fi ndings are crucial for making the 
diagnosis of CJD2,3.
We present a case of a middle-aged woman with 
progressive dementia, typical neurologic symptoms, 
positive CSF and typical MRI fi ndings. We also dis-
cuss clinical, pathologic and imaging fi ndings in this 
rare condition.
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Case Report
In May 2009, a 56-year-old woman was admit-
ted to University Department of Neurology, Dubrava 
University Hospital, due to progressive decline of cog-
nitive functions during 6 months prior to hospitaliza-
tion. Th is condition began with hand and head tremor, 
hypersensitivity to sound, disorientation in time and 
space, and inability to perform routine duties. Except 
for controlled hypertension, she was previously healthy, 
non-smoker and non-alcoholic. 
On admission, she was disoriented in time, partial-
ly disoriented in space, had voice tremor, head tremor, 
hand and leg tremor, and muscle hypertonia. Routine 
urine analysis, blood count and serum chemistry, im-
munologic blood tests and thyroid hormone levels 
were normal. She was negative for hepatitis virus A 
and B, and for human immunodefi ciency virus type 1 
and type 2. 
Initial CSF study showed normal protein, sugar 
and electrolyte content, normal blood brain barrier 
function, and was negative for neurotropic viruses and 
Borrelia burgdorferi. EEG was diff usely slow and ar-
rhythmic.
Psychological testing confi rmed specifi c clinical 
presentation of rapidly progressive dementia.
MRI of the brain (1.5 T MR imaging system, 
Avanto Siemens, Erlangen, Germany) revealed bilat-
eral and symmetrical hyperintense signal on diff usion-
weighted images, localized in the frontal, parietal and 
partially temporal cerebral cortex, caput nuclei cau-
dati and putamen (striatum), and medial and dorsal 
thalamic nuclei, followed by hypointense signal on 
apparent diff usion coeffi  cient map (ADC) (Fig. 1 a, 
b, c, d). Fluid attenuated inversion recovery (FLAIR) 
sequence revealed asymmetric and discretely hyper-
intense signal localized in the parietal and posterior 
temporal cerebral cortex, and symmetric hyperintensi-
ties of caput nuclei caudati and putamen (striatum), 
and medial and dorsal thalamic nuclei (Fig. 2). Corti-
cal and striatal hyperintensities were more pronounced 
as compared to thalamic hyperintensity. T1-weighted 
(T1WI) and T2-weighted (T2WI) images did not 
show signal intensity changes, and there was no con-
trast enhancement. Magnetic resonance spectroscopy 
(MRS) revealed decreased N-acetyl-aspartate (NAA) 
level, increased choline (Cho) level and reduced NAA/
Cho ratio.
MRI fi ndings were strongly suggestive of CJD, 
therefore repeat CSF analysis was performed only for 
CJD biomarkers, which were positive: 14-3-3 protein 
was positive, while S-100 protein (10.2 μg/L), neuron-
1a 1b
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specifi c enolase (NSE) (33.7 μg/L), and total-tau (t-
tau) protein (1190.0 pg/mL) levels were elevated.
1c 1d
Fig. 1. MRI: DWI (a, c) reveals bilateral hyperintense signal within the frontal, parietal and posterior part of temporal ce-
rebral cortex (cortical ribbon), caput nuclei caudati and putamen (striatum), and medial and dorsal thalamic nuclei (double 
hockey stick sign), followed by hypointense signal on ADC (b, d).
Fig. 2. MRI: FLAIR revealed discretely hyperintense signal 
localized in the left temporal cerebral cortex, and symmetric hy-
perintensities of the striatum and a double hockey stick sign.
Clinical presentation, MRI and CSF fi ndings, to-
gether with atypical EEG indicated CJD, therefore, 
after four-week hospital stay at our Department the 
patient was transferred to Fran Mihaljević University 
Hospital for Infectious Diseases, where she was hospi-
talized until death due to respiratory tract infection at 
the end of December 2009. During the last 6 months, 
the disease progressed with progression of neurologic 
symptoms and dementia, and development of akinetic 
mutism, so the patient was only administered symp-
tomatic therapy. Postmortem examination was not 
performed because the patient’s husband refused the 
procedure. 
Methods of Literature Search
Review of the literature was done by MEDLINE 
search of the published literature using the follow-
ing keywords: human spongiform encephalopathies, 
Creutzfeldt-Jakob disease, dementia, prion, magnetic 
resonance imaging, diff usion-weighted images, and 
diagnostic criteria. Some of the data used in this article 
are common knowledge, but most of the data used were 
abstracted from the literature listed as references.
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Discussion
Creutzfeldt-Jakob disease (CJD) is a rare, fatal 
neurodegenerative disease caused by a proteinaceous 
infectious particle that lacks nucleic acid called prion3,4. 
Prion proteins occur in both a normal form, which is 
harmless protein found in the neurons as normal cellu-
lar prion protein (PrPc), and in an infectious or patho-
logic form, called scrapie prion protein (PrPSc), which 
causes the disease4. Th e normal and pathologic forms 
of the prion protein have the same sequence of 253 
amino acids, but the pathologic form of the protein 
takes a diff erent folded shape than the normal protein. 
With time, the disease-causing PrPSc can accumulate 
and aggregate to the levels that result in brain tissue 
damage, neuronal death and development of CJD5.
Prion diseases in humans occur in three general 
forms: sporadic or spontaneous, genetic or familial, 
and acquired form. Sporadic CJD (sCJD) is the most 
common of the human prion diseases, accounting for 
approximately 85% of cases: the etiology is unknown, 
predominantly aff ects individuals aged 55-75, lasts 
from several weeks to up to two years, and the clini-
cal onset is characterized by mental-cerebellar-visual 
symptoms, comprising a broad spectrum of clinical-
pathologic variants3. Th e main causes of the pheno-
typic heterogeneity are believed to be prion strains 
(isolates that show distinct disease phenotypes upon 
transmission to syngeneic animals, persisting on se-
rial transmission), and the host genotype variability 
in the gene encoding PrPc (PRNP) located at chro-
mosome 204. In 1999, Parchi et al. established the 
molecular basis of pathologically distinct phenotypes 
of sCJD and proposed a classifi cation of sCJD ac-
cording to homozygosity or heterozygosity for me-
thionine (M) or valine (V) at the polymorphic codon 
129 of the PRNP and electrophoretic mobility of the 
protease-resistant fragment of the PrPSc (types 1 
and 2): six subtypes with distinctive phenotypic fea-
tures were defi ned6. In 2009, Parchi et al. updated the 
classifi cation including a third parameter referring to 
distinctive histopathologic features (kuru type amy-
loid plaques, predominant cortical pathology with 
confl uent vacuoles and perivacuolar PrPs staining, 
prominent thalamic pathology with atrophy): pure 
subtypes include subtypes established by previous 
nomenclature, with six new, so-called mixed  subtypes 
established by the 2009 classifi cation4.
Genetic and acquired prion diseases account for 
10%-15% and 1% of human prion diseases, respective-
ly. Th e genetic form of disease results from diff erent 
mutations in the coding region of the PRNP located 
at the short arm of chromosome 20. All of the muta-
tions are inherited in an autosomal dominant pattern. 
Depending on the mutation, the inherited forms of 
disease have been classifi ed as familial CJD, Gerst-
mann-Sträussler-Scheinker disease (GSS), and fatal 
familial insomnia (FFI). Th e most commonly occur-
ring mutation is located on codon 200 producing an 
illness that is indistinguishable from sCJD, so-called 
familial CJD. GSS typically begins at an earlier age 
than sCJD, has a prominent cerebellar component and 
evolves over a longer period of time (years rather than 
months). FFI has been named so because most pa-
tients have severe and intractable insomnia in addition 
to the usual features of CJD. Today, we know that all 
three ‘diseases’ are merely variations on a theme, and 
that all can be considered as being fundamentally the 
same and caused by the same disease process. 
Th e acquired prion diseases include kuru, iatrogenic, 
and variant CJD (vCJD). Kuru is a prion disease fi rst 
discovered in 1959 among the aboriginal Fore-people 
in the Eastern Highlands of Papua New Guinea: it 
was transmitted in connection with cannibalistic ritu-
als of eating all body parts of the deceased, including 
the brain. Th e disease has evanesced with eradication 
of cannibalism.
Th ere have been more than 400 patients that con-
tracted CJD through the use of neurosurgical instru-
ments, stereotactic EEG electrodes, human pituitary 
hormone, dura mater grafts, corneal transplant, and 
blood transfusion1,7. In previously reported case-con-
trol studies, as well as in the study by Hamaguchi et 
al., blood transfusion could be the route of secondary 
transmission, but it was never shown to be a signifi -
cant risk factor for CJD7. Th e number of new patients 
with iatrogenic CJD has decreased, but we must re-
main vigilant against prion diseases to reduce the risk 
of iatrogenesis7. 
Variant CJD (vCJD) fi rst appeared in 1996 in 
the UK: until December 2008, 210 cases of vCJD 
had been reported (164 in the UK and 46 in other 
countries)8. It is causally linked with BSE and it is 
thought to be transmitted from cattle to humans1. 
Clinically, the most striking feature of vCJD is young 
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age of its victims, ranging from 14 to 52 years, with 
an average duration of 7 to 14 months. In their study, 
Mead et al. defi ned the polymorphic codon 129 of 
PRNP as the main genetic risk factor for vCJD9. At 
the beginning of vCJD, psychiatric or sensory symp-
toms predominate. 
Th e neuropathology of CJD is characterized by 
spongiform degeneration (vacuolation) of neurons, 
neuronal loss, intense reactive astrocytic proliferation, 
and accumulation of PrPSc, possibly forming plaques5. 
Spongiform degeneration involves cerebral cortex, 
striatum, thalamus and cerebellar cortex, and it is the 
most prominent histologic feature characterized by 
numerous oval and rounded vacuoles in the neuropil 
between the nerve cell bodies that occur both singly 
and in confl uent groups resulting in large vacuoles that 
substantially distort the cytoarchitecture5. Th e spongi-
form change results in neuronal loss, gliosis and severe 
brain atrophy. A large number of amyloid plaques sur-
rounded by a halo spongiform changes called ‘fl orid 
plaques’ are diagnostic for vCJD3,5.
Th e incubation period of CJD ranges from 3 to 22 
years, with subacute onset and progressive deteriora-
tion10. Clinical presentation of CJD is characterized 
by psychiatric and neurologic symptoms, and visual 
impairment that may progress to blindness. Rapidly 
progressive dementia is the most striking symptom. 
Initially, patients experience problems with muscular 
coordination; personality changes, including impaired 
memory, judgment, and thinking; and blurred vision. 
People with the disease may also experience insom-
nia, depression, or unusual sensations. As the illness 
progresses, the patients’ mental impairment becomes 
severe, they develop myoclonus, pyramidal and ex-
trapyramidal symptoms. Eventually, the state of aki-
netic mutism develops and the patients enter coma. 
Pneumonia and other, usually respiratory infections 
often occur in these patients and lead to death.
Th e diagnosis of CJD relies on a combination of 
clinical presentation, neurologic testing, pathologic 
examination, and cross-sectional imaging. Because 
CJD is such a rare disease, initial laboratory studies 
are aimed at ruling out all other potential endocrine, 
infectious, neoplastic, metabolic, and neurologic disor-
ders. Other diagnostic procedures include CSF analy-
sis, EEG, MRI and MRS, and brain biopsy, possibly 
tonsil biopsy3.
CSF analysis is necessary for two reasons: to rule 
out other etiologies such as infections or autoimmune 
conditions, and to detect biomarkers for CJD (neu-
ronal proteins released into the CSF during extensive 
brain tissue destruction) such as the 14-3-3 protein, 
NSE, S-100 protein and t-tau3,11,12. In two thirds of 
sCJD cases, EEG shows typical pattern of ‘periodic 
slow and sharp wave’ complexes, or it can show a less 
defi nite but still suggestive pattern of ‘burst wave sup-
pression’. Regarding vCJD, EEG is usually unspecifi c, 
but without complexes typical or suggestive of CJD. 
Periodic slow and sharp wave complexes in EEG 
and elevated 14-3-3 protein in CSF are considered to 
be reliable criteria for the diagnosis of CJD13. In our 
case, clinical presentation and CSF fi ndings were sug-
gestive of CJD, while EEG was unspecifi c.
Neuroimaging has dramatically changed our abil-
ity to accurately diagnose dementia: currently, MRI 
is more useful for the diagnosis of prion disease than 
for any other dementia14. Computed tomography is 
not useful in the diagnosis of CJD because it will only 
reveal brain atrophy. MRI is an important diagnostic 
tool in CJD not only for making the diagnosis of CJD, 
but for ruling out the other possible etiologies and 
monitoring changes during the course of disease.
Characteristic MRI fi ndings in CJD are best seen 
on diff usion-weighted images (DWI) and to a lesser 
extent on FLAIR images, and are 91% sensitive and 
95% specifi c for the diagnosis of CJD15. Th ese fi ndings 
include hyperintense signals within the cerebral cor-
tex called ‘cortical ribbon’, within caput nuclei caudate 
and putamen (striatum), and thalamus2,3. Th e ‘double 
hockey stick sign’ refers to increased signal in the me-
dial and dorsal thalamic nuclei, while the ‘pulvinar sign’ 
refers to increased signal in the dorsal thalamic nuclei, 
called pulvinar. Hyperintense signal on DWI is fol-
lowed by hypointense signal in ADC map, and refl ects 
restricted diff usion of water molecules at the micro-
scopic level due to numerous, small sized vacuoles and 
accumulation of PrPSc, while hyperintense signal on 
FLAIR is due to reactive gliosis2,3. Th ese changes will 
not show contrast enhancement after its application.
In the early phase of CJD, signal changes are de-
tected earliest on DWI, less frequently on FLAIR, 
while signal intensity is normal on T1WI and T2WI. 
With disease progression, there is an expansion of 
signal changes and progressive cerebral atrophy16. In 
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late stages of CJD, hyperintense signal on DWI may 
disappear with normalization on ADC due to reactive 
gliosis16. In the end stage, there is severe cerebral and 
cerebellar atrophy and atrophy of the brain stem with 
ventricular enlargement.
Cortical signal changes in CJD involve all lobes, 
mainly frontal (89%), limbic (79%), parietal (72%) and 
temporal (65%) cortex, while the precentral and cen-
tral gyri are usually spared. In the majority of cases, 
hyperintensities in cortex and striatum are symmetric, 
although an unilateral predominance is possible3,17.
In sCJD, hyperintense signals in cerebral cortex 
and striatum are the most common MRI fi ndings. 
Hyperintensities in the pulvinar thalami have also 
been reported in sCJD, but they are usually less pro-
nounced than in the striatum, whereas in vCJD the 
highest signal is always in the pulvinar17.
In comparison with literature data, in our case 
MRI fi ndings strongly indicated CJD: typical corti-
cal and striatal hyperintensities, and medial and dor-
sal thalamic nuclei hyperintensities were present and 
more pronounced on DWI as compared to FLAIR, 
and more pronounced in the cortex and striatum than 
in the thalamus3,16,17. 
Magnetic resonance spectroscopy (MRS) is a non-
invasive technique that allows for evaluation of spe-
cifi c brain metabolites, including N-acetyl-aspartate 
(NAA) as a neuronal marker, creatine (Cr) as a marker 
of neuronal metabolism, and myoinositol (mI) as a glial 
marker. In CJD, MRS reveals reduced NAA content 
and/or increased mI content in the aff ected areas due 
to neuronal loss and reactive gliosis, followed by marked 
reduction of the NAA/Cr and NAA/mI ratios12.
Positive pathologic fi ndings on brain biopsy or au-
topsy confi rm the diagnosis of CJD, including immu-
nohistochemical detection of the pathologic protein 
(PrPSc)3. Autopsy of patients with CJD is always per-
formed in autopsy examination halls specially aimed 
for patients with prion diseases.
Brain biopsy for CJD can be a dangerous procedure 
and is not performed routinely because of the previ-
ously mentioned and accepted diagnostic procedures, 
and possible false-negative fi ndings3. It is only advis-
able when an alternative treatable disease is suspected. 
Due to the route of infection in vCJD, PrPSc infects 
peripheral lymphoid tissue like tonsils. Th erefore, in 
vCJD it is possible to confi rm the diagnosis with tonsil 
biopsy9. Because of the possible complications for the 
patient and the risk of infection for the team, the pro-
cedure is only performed in clinically diffi  cult cases3. 
In our case, tonsil biopsy was not performed be-
cause of the reasons mentioned above and because we 
presumed an autopsy should be performed after the 
patient’s death. Unfortunately, although autopsy was 
strongly advised to the family and the patient’s daugh-
ter was in favor of the procedure, the patient’s husband 
refused it for reasons that are unknown to us.
Radiological diff erential diagnosis includes Leigh’s 
disease, carbon monoxide poisoning, cerebral hypoxia, 
cortical ischemia, postictal changes, encephalitis, and 
possibly tumors (lymphoma and metastases)3. Clinical 
picture of progressive dementia in combination with 
the neuroimaging fi ndings described should lead to 
the diagnosis of CJD.
Treatment for all forms of CJD is largely symp-
tomatic, as no established curative agents have been 
identifi ed. A number of diff erent experimental agents 
are currently under investigation including quinacrine, 
which prevented conversion of PrPC to PrPSc in in 
vitro studies18. Pentosan polysulfate has been shown to 
increase incubation time in animal studies by aff ecting 
prion production, replication and the associated cell 
toxicity, but data in humans are not clear(19). Flupir-
tine20 demonstrated a trend towards improving cogni-
tive function but showed no survival improvement.
Since postmortem examination was not performed, 
we could not reach defi nitive confi rmation; clinical 
presentation, CSF and MRI fi ndings were typical for 
CJD, but distinction between the forms of the disease 
was missing. Th ere are no heterohistory data suggest-
ing the possibility that the patient had a familial form 
of CJD. Th e course of the disease, the patient’s age and 
MRI fi ndings suggested a sporadic form of CJD, while 
clinical presentation and duration of about 12 months 
could indicate both sporadic and variant form of the 
disease. In conclusion, we presume that our patient 
probably had a sporadic form of CJD3,11,16,17.
Th e aim of this case report and review of the lit-
erature is to emphasize the possibility of CJD in a 
small population like Croatian and encourage our col-
leagues, neurologists and radiologists, to think of it in 
their practice when encountering a young or middle-
aged patient with clinical presentation and imaging 
fi ndings similar to those described above.
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Sažetak
CREUTZFELDT-JAKOBOVA BOLEST: PRIKAZ SLUČAJA I PREGLED LITERATURE
M. Špero i I. Lazibat
Creutzfeldt-Jakobova bolest (CJD) je rijetka i smrtonosna neurodegenerativna bolest koju uzrokuje infektivna bjelan-
čevina nazvana prion, a obilježena je spužvastim promjenama, gubitkom neurona, reaktivnom proliferacijom astrocita i 
nakupljanjem patološke stanične bjelančevine. Bolest se javlja u tri glavna oblika: sporadični ili spontani, genetski ili obi-
teljski, te stečeni oblik uključujući varijantni oblik CJD. Klinički je CJD obilježena progresivnom demencijom, neurološ-
kim simptomima i poremećajem vida, razvojem akinetskog mutizma, te konačno smrću, najčešće zbog dišne infekcije. Di-
jagnoza se temelji na kliničkim značajkama, elektroencefalogramu, te tipičnim nalazima likvora i magnetske rezonancije. 
Prikazuje se slučaj 56-godišnje bolesnice s progresivnom demencijom, tipičnim neurološkim simptomima, te pozitivnim 
nalazima likvora i magnetske rezonancije. Također se raspravlja o kliničkim i patološkim nalazima, te nalazima slikovnog 
prikazivanja u ovoj rijetkoj bolesti.
Ključne riječi: Creutzfeldt-Jakobov sindrom – dijagnostika; Creutzfeldt-Jakobov sindrom – etiologija; Prioni; Magnetska 
rezonancija; Moždana patologija; Ljudi; Prikaz slučaja
